RxDoctor Payments Data

Kimberly Jones, NP

Nurse Practitioner · Dublin, OHNPI 1093792228

Payments from drug & device makers

$1,231in general payments, 2019–2025

Across 54 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$654
  • Atricure, Inc.$166
  • Amgen$122
  • Boehringer Ingelheim$98
  • Novo Nordisk$60
  • Abbott$46
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$1,20998%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,231 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$20,494
Medicare patients
70
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$57,823
MounjaroTirzepatide16$14,387
SynthroidLevothyroxine Sodium14$1,885
Atorvastatin Calcium70$667
Bupropion XlBupropion Hcl14$590
Pantoprazole Sodium23$553
Omeprazole52$461
Lisinopril58$434
Simvastatin44$431
Losartan Potassium37$369
Escitalopram Oxalate23$351
Metoprolol Succinate26$322
Rosuvastatin Calcium56$304
Sumatriptan Succinate14$295
Levothyroxine Sodium43$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$60$57,82337 claims
AbbVieSynthroid$654$1,88514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →